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A cute pancreatitis is the most important compli-cation of endoscopic retrograde cholangiopan-
creatography (ERCP).  Generally,  post-ERCP pan-
creatitis (PEP) occurs in 1-25  of patients ［1-2］.  
PEP is usually mild or moderate,  however,  some 
cases involve the development of severe pancreatitis,  
which requires further intervention and leads to death 
in 0.3–0.6  of the patients ［3-6］.
　 Numerous pharmacological procedures have been 
evaluated for the prevention of PEP.  Several ran-
domized trials including a high-proﬁle multicenter 
study have conﬁrmed the eﬃcacy of rectal nonsteroi-
dal anti-inﬂammatory drugs (NSAIDs) in preventing 
PEP ［7-10］.  Therefore,  routine rectal administra-
tion of diclofenac or indomethacin,  immediately before 
or after ERCP is recommended to minimize the risk 
for PEP ［11］.  Moreover,  in two randomized con-
trolled trials (RCTs),  positive results were obtained 
by administering sublingual nitroglycerin to prevent 
PEP ［12,13］.  Nitroglycerin is a smooth-muscle relax-
ant,  which may lower the sphincter of Oddi pressure 
and increase pancreatic parenchymal blood ﬂow ［14］.
　 Recently,  it was demonstrated in an RCT that a 
combination of sublingual nitroglycerin and a rectal 
NSAIDs was more eﬀective than only NSAIDs for 
preventing PEP ［15］.  The study showed that the 
relative risk for PEP was reduced by 56.2  with the 
treatment,  which is simple,  inexpensive,  and well 
tolerated.  Although the trial showed eﬃcacy of the 
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Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography 
(ERCP).  A preliminary research suggested that the administration of nonsteroidal anti-inﬂammatory 
drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more 
eﬀectively than NSAIDs alone.  We conduct a two-arm,  multicenter,  prospective,  randomized,  superi-
ority trial to evaluate the additional eﬀect of nitroglycerin for prevention of PEP.  A total of 900 
patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate 
sublingual tablet.  The primary endpoint is the occurrence of PEP.  This study will clarify whether 
NSAIDs plus nitroglycerin can prevent PEP.
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combination therapy for preventing PEP,  the trial was 
a single-center study with small sample size.  
Therefore,  we conduct a multicenter,  prospective,  
randomized controlled trial to evaluate the eﬃcacy of 
a combination of rectal NSAIDs and sublingual nitro-
glycerin for preventing PEP.
Methods
　 Study design. The study is a two-arm,  multi-
center,  prospective,  randomized,  superiority trial to 
evaluate the additional eﬀect of nitroglycerin with 
diclofenac for prevention of PEP,  and compare it with 
that of diclofenac alone.  The study is conducted at the 
Okayama University Hospital and 11 other hospitals 
aﬃliated to the Okayama University.  A total of 900 
eligible patients are randomly assigned to receive 
50 mg diclofenac suppository either alone or with 5 mg 
isosorbide dinitrate sublingual tablet.  The sublingual 
tablets are administered 5 min before ERCP and the 
diclofenac suppositories are administered in 15 min 
after ERCP (Fig.  1).
Ethical consideration
　 The study protocol is approved by the institutional 
review board of each participating institution before 
the study is initiated (no. m02027).  This trial is regis-
tered with the University hospital Medical Information 
Network Clinical Trial Registry (no. UMIN000016274).
Endopoints
　 Primary and secondary endpoints. The pri-
mary endpoint is the occurrence of PEP.  PEP is 
deﬁned by the criteria set by Cotton et al.  ［16］,  as 
the development of abdominal pain and elevation of 
serum amylase levels by more than 3 times the upper 
normal limit (hyperamylasemia) within 24 h after 
ERCP.  Serum amylase level is measured before 
ERCP and at any time when the patient complains of 
abdominal pain within 24 h after ERCP; otherwise,  it 
is routinely measured 24 h after ERCP.  Secondary 
endpoints include the development of moderate or 
severe PEP,  the frequency of PEP in patients with 
risk factors for PEP,  risk factors for PEP in this 
study,  and adverse eﬀects related to the study drugs.  
The severity of PEP is graded according to the dura-
tion of fasting period after the ERCP.  Mild PEP 
required 2–3 days; moderate PEP required 4–10 
days; and severe PEP required more than 10 days,  
necessitating a surgical or intensive treatment,  or 
resulting in death.  The following procedures are con-
sidered high-risk for PEP: (1) precut sphincterotomy 
(a procedure performed to facilitate biliary access 
when standard cannulation techniques are unsuccess-
ful),  (2) endoscopic pancreatic sphincterotomy 
(EPST),  (3) endoscopic papillary balloon dilation 
(EPBD) without endoscopic sphincterotomy (EST),  
(4) diﬃcult cannulation (more than 10 min elapsed for 
successful cannulation,  (5) failed cannulation,  (6) 
injection of contrast agent into the pancreatic duct,  (7) 
female sex and age＜60 years,  (8) clinical suspicion of 
sphincter of Oddi dysfunction (SOD),  (9) history of 
recurrent pancreatitis,  and (10) history of PEP 
(11,17).  The patients- and procedure-related factors 
are recorded at the end of procedures and risk factors 
for PEP are evaluated.  Patient-related factors 
include following: (1) age,  (2) sex,  (3) presence of 
parapapillary diverticulum,  and (4) indication of 
ERCP.  Procedure-related factors include follow-
ing: (1) pancreatography,  (2) pancreatic acinarization 
on radiography,  (3) EPST,  (4) precut sphincterot-
omy,  (5) EST,  (6) EPBD without EST,  (7) endo-
scopic biliary drainage without EST,  (8) pancreatic 
duct stenting,  (9) pancreatic duct-intraductal ultraso-
nography,  (10) common bile duct-intraductal ultraso-
nography,  (11) common bile duct tissue sampling; cy-
tology and brush,  (12) pancreatic duct tissue 
sampling; cytology and brush,  (13) time of cannula-
tion,  and (14) total time of procedure.
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900 eligible patients randomized 
as per protocol 
450 patients receive 
diclofenac and isosorbide dinitrate 
450 patients receive
diclofenac alone 
Fig. 1　 Flow diagram of rectal diclofenac and sublingual isosor-
bide dinitrate versus diclofenac alone for the prevention of post-
ERCP pancreatitis.
Eligibility Criteria
　 All of the patients who meet the inclusion criteria 
and exclusion criteria,  which are listed in Table 1,  
are enrolled in this study from March 2015 to 
February 2018.  
Randomization
　 After conﬁrming fulﬁllment of the eligibility crite-
ria,  registration to the Data Center is conducted by a 
web-based system.  Patients are then randomly 
assigned to receive a 50 mg diclofenac suppository,  
either alone or in combination with a 5 mg isosorbide 
dinitrate sublingual tablet by a minimization method 
balancing the arms with institution,  age,  sex,  and 
primary disease (hepatibiliary disease vs.  pancreatic 
disease).  
Treatment Methods
　 Intervention. Before the endoscopy,  the his-
tory of each patient is recorded and a physical exam-
ination is performed.  Pharyngeal anesthesia is induced 
with a topical anesthetic,  whereas conscious sedation 
is induced with an intravenous medication.  We admin-
ister 20 ml of ulinastatin (150,000 U) solution,  a pro-
teolytic enzyme solution,  by intravenous infusion 
immediately after the ERCP.  The ERCP devices 
used are not limited to any speciﬁc types.  A contrast 
agent is injected prior to the procedures,  as is the 
custom in Japan.  In cases in which it is diﬃcult to 
cannulate,  we perform pancreatic guidewire placement 
or precut sphincterotomy to achieve selective cannula-
tion.  Pancreatic duct stenting is performed to prevent 
pancreatitis at the endoscopistʼs discretion.  After the 
procedures,  the endoscopists record the results and 
patients fasted until blood tests performed the follow-
ing day conﬁrmed the absence of pancreatitis or other 
complications.  All patients are hospitalized for the 
ERCP procedure and observation.
　 Adverse effects. Adverse eﬀects of the study 
drugs are monitored during their hospital stay.  
Adverse eﬀects of diclofenac,  including gastrointesti-
nal bleeding and renal failure,  and adverse eﬀects of 
nitrates,  including headache,  dizziness,  and reduction 
in systolic blood pressure are monitored.  Other post-
ERCP adverse events,  including cholangitis,  bleeding,  
and perforation are monitored in addition to PEP.
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Table 1　 Inclusion and exclusion criteria of the study
Inclusion criteria
Patients who are scheduled to undergo ERCP
Patients who can provide written informed consent
Exclusion criteria
Performance status of 4
Younger than 20 years,
Body weight less than 50 kg
Duodenal papilla not accessible endoscopically
History of EST or EPBD
Presence of acute pancreatitis
Presence of chronic pancreatitis
Presence of pancreatic head cancer with occlusion of the MPD
Contraindication to NSAIDs or nitroglycerin
Cases of post gastrectomy
Creatinine level, ＞1.4 mg per deciliter
Presence of active peptic ulcer disease
Presence of closed angle glaucoma
Presence of aspirin-induced asthma
Currently taking nitroglycerin
Inability to provide written informed consent
Subjects deemed inappropriate for the trial
ERCP,  endoscopic retrograde cholangiopancreatography; EST,  endoscopic sphincterotomy; EPBD,  endoscopic papillary balloon dila-
tion; MPD,  main pancreatic duct; NSAIDs,  nonsteroidal anti-inﬂammatory drugs.
Statistic Consideration
　 Sample size. Previous data from a meta-analy-
sis conducted by Puig et al. ［18］ indicated that prophy-
lactic administration of rectal NSAIDs reduced the 
incidence of PEP from 14.5  to 7.4 ,  and the rela-
tive risk reduction was 50.7 .  Sotoudehmanesh et al. 
［15］ also reported that combining rectal NSAIDs with 
sublingual nitroglycerin reduced the incidence of PEP 
from 15.3  to 6.7 ,  compared with NSAIDs alone,  
and the relative risk reduction was 56.2 .
　 We assumed that the incidence of PEP in the 
patients who did not receive any prophylactic medicine 
for PEP would be 14.6  (estimated from data obtained 
in the previous 5 years from our institutions).  We esti-
mated that 892 patients (446 per study group) would 
provide a power of at least 80  to detect a 56.2  
reduction in the incidence of PEP,  from 7.4  (in the 
group administered only diclofenac) to 3.2  (in group 
administered the combined treatment),  by Fisherʼs 
exact test with a two-sided signiﬁcance level of 0.05.
　 Statistical analysis. Statistical analysis is 
performed on the basis of intention-to-treat analysis.  
The Wilcoxon rank sum test is performed to compare 
the continuous data and the chi-square test is per-
formed to evaluate non-continuous variables.  A p-value
＜0.05 is considered signiﬁcant.  Initial univariate 
evaluations are made for each potential risk factor by 
the chi-square test.  Only the signiﬁcant factors from 
the chi-square analysis are included in multivariate 
analyses.  All statistical analyses are performed using 
JMP 9 (SAS Institute Inc.,  Cary,  NC,  USA).  The 
ranges of continuous values are shown as interquartile 
ranges.
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